140 related articles for article (PubMed ID: 24439053)
21. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.
Baron F; Labopin M; Niederwieser D; Vigouroux S; Cornelissen JJ; Malm C; Vindelov LL; Blaise D; Janssen JJ; Petersen E; Socié G; Nagler A; Rocha V; Mohty M
Leukemia; 2012 Dec; 26(12):2462-8. PubMed ID: 22699419
[TBL] [Abstract][Full Text] [Related]
22. Extensive dental caries in patients with oral chronic graft-versus-host disease.
Castellarin P; Stevenson K; Biasotto M; Yuan A; Woo SB; Treister NS
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1573-9. PubMed ID: 22516054
[TBL] [Abstract][Full Text] [Related]
23. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Lee KH; Choi SJ; Lee JH; Lee JS; Kim WK; Lee KB; Sohn SK; Kim JG; Kim DH; Seol M; Lee YS; Lee JH
Haematologica; 2005 Jul; 90(7):939-48. PubMed ID: 15996932
[TBL] [Abstract][Full Text] [Related]
25. High levels of B cell activating factor during the peritransplantation period are associated with a reduced incidence of acute graft-versus-host disease following myeloablative allogeneic stem cell transplantation.
Cho BS; Min CK; Kim HJ; Lee S; Kim YJ; Lim JY; Jeong DC; Cho B; Kim HK; Eom KS; Cho SG; Kim DW; Lee JW; Min WS; Kim CC; Chung NG
Biol Blood Marrow Transplant; 2010 May; 16(5):629-38. PubMed ID: 19963070
[TBL] [Abstract][Full Text] [Related]
26. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.
Pérez-Simón JA; Díez-Campelo M; Martino R; Brunet S; Urbano A; Caballero MD; de León A; Valcárcel D; Carreras E; del Cañizo MC; López-Fidalgo J; Sierra J; San Miguel JF
Br J Haematol; 2005 Aug; 130(3):394-403. PubMed ID: 16042689
[TBL] [Abstract][Full Text] [Related]
27. Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease.
Balon J; Hałaburda K; Bieniaszewska M; Reichert M; Bieniaszewski L; Piekarska A; Pawłowski R; Hellmann A
Bone Marrow Transplant; 2005 Jun; 35(11):1083-8. PubMed ID: 15821766
[TBL] [Abstract][Full Text] [Related]
28. [Clinical significance of formation and conversion of hematopoietic mixed chimerism in nonmyeloablative allogeneic stem cell transplantation].
Ai HS; Yu CL; Wang DH; Guo M; Qiao JH; Shi BF; Sun WJ; Zhang S; Sun QY; Yao B
Zhonghua Yi Xue Za Zhi; 2003 Feb; 83(3):208-11. PubMed ID: 12812663
[TBL] [Abstract][Full Text] [Related]
29. Risk assessment and outcome of chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell transplantation in pediatric patients.
Diaz MA; Vicent MG; Gonzalez ME; Verdeguer A; de la Rubia J; Bargay J; de Arriba F; Diez JL; Caballero D; Madero L; Brunet S;
Bone Marrow Transplant; 2004 Sep; 34(5):433-8. PubMed ID: 15273704
[TBL] [Abstract][Full Text] [Related]
30. [Relationship between WT1-specific T-cell subsets and graft-versus-host disease after nonmyeloablative allogeneic transplantation].
Wei L; Zuo HL; Liu TQ; Sun XD; Guo M; Liu GX; Sun QY; Qiao JH; Wang DH; Yu CL; Hu KX; Dong Z; Ai HS
Zhonghua Xue Ye Xue Za Zhi; 2011 Feb; 32(2):89-93. PubMed ID: 21429373
[TBL] [Abstract][Full Text] [Related]
31. High incidence of chronic graft versus host disease after allogeneic peripheral blood progenitor cell transplantation. The Spanish Group of Allo-PBPCT.
Urbano-Ispizua A; García-Conde J; Brunet S; Hernández F; Sanz G; Petit J; Bargay J; Figuera A; Rovira M; Solano C; Ojeda E; de la Rubia J; Rozman C
Haematologica; 1997; 82(6):683-9. PubMed ID: 9499667
[TBL] [Abstract][Full Text] [Related]
32. Acquired ichthyosis associated with chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation in a patient with chronic myelogenous leukemia.
Dilek I; Demirer T; Ustün C; Arat M; Koç H; Beksaç M; Erdi H; Anadolu R; Ozcan M; Ilhan O; Akan H
Bone Marrow Transplant; 1998 Jun; 21(11):1159-61. PubMed ID: 9645582
[TBL] [Abstract][Full Text] [Related]
33. Female genital chronic graft-versus-host disease: importance of early diagnosis to avoid severe complications.
Hirsch P; Leclerc M; Rybojad M; Petropoulou AD; Robin M; Ribaud P; de la Tour RP; Cavelier-Balloy B; Socié G; Vexiau-Robert D
Transplantation; 2012 Jun; 93(12):1265-9. PubMed ID: 22466789
[TBL] [Abstract][Full Text] [Related]
34. Peripheral blood lymphocyte and monocyte recovery and survival in acute leukemia postmyeloablative allogeneic hematopoietic stem cell transplant.
Thoma MD; Huneke TJ; DeCook LJ; Johnson ND; Wiegand RA; Litzow MR; Hogan WJ; Porrata LF; Holtan SG
Biol Blood Marrow Transplant; 2012 Apr; 18(4):600-7. PubMed ID: 21843495
[TBL] [Abstract][Full Text] [Related]
35. Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease.
Yanada M; Naoe T; Iida H; Sakamaki H; Sakura T; Kanamori H; Kodera Y; Okamoto S; Kanda Y; Sao H; Asai O; Nakai K; Maruta A; Kishi K; Furukawa T; Atsuta Y; Yamamoto K; Tanaka J; Takahashi S
Bone Marrow Transplant; 2005 Nov; 36(10):867-72. PubMed ID: 16113659
[TBL] [Abstract][Full Text] [Related]
36. The impact of HLA-E polymorphisms in graft-versus-host disease following HLA-E matched allogeneic hematopoietic stem cell transplantation.
Hosseini E; Schwarer AP; Ghasemzadeh M
Iran J Allergy Asthma Immunol; 2012 Mar; 11(1):15-21. PubMed ID: 22427472
[TBL] [Abstract][Full Text] [Related]
37. Validation of the human activity profile questionnaire in patients after allogeneic hematopoietic stem cell transplantation.
Herzberg PY; Heussner P; Mumm FH; Horak M; Hilgendorf I; von Harsdorf S; Hemmati P; Rieger K; Greinix H; Freund M; Lee SJ; Holler E; Wolff D
Biol Blood Marrow Transplant; 2010 Dec; 16(12):1707-17. PubMed ID: 20541028
[TBL] [Abstract][Full Text] [Related]
38. Gene expression profile of cytokines in patients with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with reduced conditioning.
Poloni A; Sartini D; Emanuelli M; Trappolini S; Mancini S; Pozzi V; Costantini B; Serrani F; Berardinelli E; Renzi E; Olivieri A; Leoni P
Cytokine; 2011 Mar; 53(3):376-83. PubMed ID: 21211989
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of autoantibody expression in allogeneic stem-cell recipients.
Moon JH; Lee SJ; Kim JG; Chae YS; Kim SN; Kang BW; Suh JS; Lee KS; Sohn SK
Transplantation; 2009 Jul; 88(2):242-50. PubMed ID: 19623021
[TBL] [Abstract][Full Text] [Related]
40. Allogeneic peripheral blood stem cell transplantation significantly increases risk of chronic graft-versus-host disease of lung compared with bone marrow transplantation.
Alam N; Marras TK; Atenafu EG; Gupta V; Kuruvilla J; Lipton JH; Messner HA; Kim DD
Biol Blood Marrow Transplant; 2012 Dec; 18(12):1905-10. PubMed ID: 22835425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
